Trimel's sexual disorder drug effective in mid-stage study

Send a link to a friend  Share

[May 28, 2014]  (Reuters) - Trimel Pharmaceuticals Corp said its experimental sexual disorder drug increased the average number of orgasms in women with an orgasmic disorder in a second mid-stage study.

The company said its lowest tested dose of 0.6 mg of the nasal drug Tefina showed a statistically significant increase, compared with a placebo, in the number of orgasms in pre- and post-menopausal patients with female orgasmic disorder.

The study, which tested three doses of the drug, enrolled 253 patients who were treated over 84 days in a home setting, Trimel said.

The company did not report the findings from the other two tested doses of Tefina, a low-dose gel formulation of testosterone.

Trimel reported in February 2012 that the drug improved the occurrence of orgasms in a smaller mid-stage study conducted in a hospital setting.

Trimel said on Wednesday that the drug improved sexual functioning and satisfaction, and reduced distress. It was also well-tolerated, with no serious adverse events reported.

Female orgasmic disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasms, leading to distress.

There is no approved treatment for the condition, but patients are often given hormone tablets and patches.

[to top of second column]

Trimel's stock closed at 70 Canadian cents on Tuesday on the Toronto Stock Exchange.

(Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey and Savio D'Souza)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top